Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients

References

• Greb JE, Goldminz AM, Gottlieb AB. Insights on methotrexate in psoriatic disease. Clin Immunol. 2016;172:61–64.
   PubMed Web of Science ®Google Scholar
• Bujor AM, Janjua S, LaValley MP, et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS One. 2019;14(9):e0221823.
   PubMed Web of Science ®Google Scholar
• Naz F, Kumar Dinda A, Kumar A, et al. Investigation of ultrafine gold nanoparticles (AuNPs) based nanoformulation as single conjugates target delivery for improved methotrexate chemotherapy in breast cancer. Int J Pharm. 2019;569:118561.
   PubMedGoogle Scholar
• Green K, Hogg JP. Cancer, central nervous system lymphoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019.
   Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui C-H, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Bleyer WA. The clinical pharmacology of methotrexate.new applications of an old drug. Cancer. 1978;41(1):36–51.
   PubMed Web of Science ®Google Scholar
• Ranchon F, Vantard N, Henin E, et al. Delayed methotrexate elimination: incidence, interaction with antacid drugs, and clinical consequences? Hematol Oncol. 2018;36(2):399–406.
   PubMed Web of Science ®Google Scholar
• Drost SA, Wentzell JR, Giguère P, et al. Outcomes associated with reducing the urine alkalinization threshold in patients receiving high-dose methotrexate. Pharmacotherapy. 2017;37(6):684–691.
   PubMed Web of Science ®Google Scholar
• Shalaby YM, Menze ET, Azab SS, et al. Involvement of Nrf2/HO-1 antioxidant signaling and NF-κB inflammatory response in the potential protective effects of vincamine against methotrexate-induced nephrotoxicity in rats: cross talk between nephrotoxicity and neurotoxicity. Arch Toxicol. 2019;93(5):1417–1431.
   PubMed Web of Science ®Google Scholar
• Mikkelsen TS, Mamoudou AD, Tuckuviene R, et al. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study. Pediatr Blood Cancer. 2014;61(2):297–301.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100(10):2222–2232.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Buse JB, Tuomilehto J, et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a diabetes care editors' expert forum. Diabetes Care. 2016;39(7):1186–1201.
   PubMed Web of Science ®Google Scholar
• Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(8):1366–1373.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13(11):697–711.
   PubMed Web of Science ®Google Scholar
• Coleman MD, Shaefi S, Sladen RN. Preventing acute kidney injury after cardiac surgery. Curr Opin Anaesthesiol. 2011;24(1):70–76.
   PubMed Web of Science ®Google Scholar
• Fähling M, Seeliger E, Patzak A, et al. Understanding and preventing contrast-induced acute kidney injury. Nat Rev Nephrol. 2017;13(3):169–180.
   PubMed Web of Science ®Google Scholar
• He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071–1083.
   PubMed Web of Science ®Google Scholar
• Qi H, Casalena G, Shi S, et al. Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes. 2017;66(3):763–778.
   PubMed Web of Science ®Google Scholar
• Yamahara K, Kume S, Koya D, et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol. 2013;24(11):1769–1781.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang X, Tian J, et al. Renal Function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate. Med Sci Monit. 2018;24:7719–7726.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
   PubMed Web of Science ®Google Scholar
• Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from kidney disease: improving global outcomes. Kidney Int. 2015;87(1):20–30.
   PubMed Web of Science ®Google Scholar
• Grams ME, Astor BC, Bash LD, et al. Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. JASN. 2010;21(10):1757–1764.
   Web of Science ®Google Scholar
• James MT, Hemmelgarn BR, Wiebe N, Alberta Kidney Disease Network, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet. 2010;376(9758):2096–2103.
   PubMed Web of Science ®Google Scholar
• Grams ME, Sang Y, Ballew SH, et al.; CKD Prognosis Consortium. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis. 2015;66(4):591–601.
   PubMed Web of Science ®Google Scholar
• Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58–66.
   PubMed Web of Science ®Google Scholar
• Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765–1776.
   PubMed Web of Science ®Google Scholar
• Abate N, Chandalia M, Cabo-Chan AV, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386–392.
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Cameron MA, Moe OW, et al. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2(5):883–888.
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Cameron MA, Moe OW, et al. Metabolic basis for low urine pH in type 2 diabetes. CJASN. 2010;5(7):1277–1281.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA, Dubree M, Zhang J, et al. Effect of renal lipid accumulation on proximal tubule Na+/H + exchange and ammonium secretion. Am J Physiol Renal Physiol. 2008;294(6):F1315–F1322.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA, Dubree M, Zhang J, et al. Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H + exchange and urinary acidification. Am J Physiol Renal Physiol. 2009;297(5):F1419–F1426.
   PubMed Web of Science ®Google Scholar